

BILL SUMMARY
2nd Session of the 57th Legislature

Bill No.:	HB 3418
Version:	Introduced
Request Number:	10343
Author:	McEntire
Date:	2/12/2020
Impact:	None

Research Analysis

HB 3418 exempts distributors of peritoneal dialysis drugs and devices, used to treat end-stage renal disease (ESRD), from State Board of Pharmacy licensure requirements. Exempt distributors must ensure that the drugs and devices are FDA-approved, held by a licensed manufacturer, delivered in original packaging, and only delivered pursuant to a prescription. The drugs and devices must be directly delivered to the patient or health care provider.

Prepared By: Anna Rouw

Fiscal Analysis

HB 3418 has no costs anticipated to the agency.

Prepared By: Stacy Johnson

Other Considerations

None.